May 16, 2023

Democratizing RNA sequencing: A breakthrough in cost and efficiency

CSEM has supported the Lausanne-based start-up Alithea Genomics in developing a technology capable of processing hundreds of ribonucleic acid (RNA) samples in a single tube, which translates to a significant reduction in reagents and manual effort in the overall workflow.

Alithea team
© CSEM - Erfolgreiche Zusammenarbeit zwischen dem Start-up Alithea und dem Schweizer Technologie-Innovationszentrum CSEM (von links nach rechts): Vincent Revol (CSEM, Co-Head Research & Business Development Life Science Technologies), Daria Gudkova (Alithea, Product Manager), Stéphanie Boder-Pasche (CSEM, Senior Project Manager Cell Microtechnologies), Marine Vallez (Alithea, Wissenschafterin in F&E) und Gilles Weder (CSEM, Co-Head Research & Business Development Life Science Technologies). In ihren Händen halten sie ein Alithea-Reagenz-Kit.

Related Press

Group of 7 persons, members of the CSEM and the TheraMe teams

23 January 2025

CSEM and TheraMe! revolutionize cancer therapy with personalized drug screening technology

What if there was a solution allowing to test which drug or drug combination works best on the tumor cells of a given patient at any given stage of the disease?...

A hand holding a bioreactor to grow vein grafts developed by CSEM and ClexBio

22 February 2024

CSEM and ClexBio create a bioreactor for tissue-engineered cardiovascular implants

The teams at CSEM and at ClexBio have developed a process for engineering vein grafts comprised of human tissue material that integrates into the patient’s body and can turn into real, living tissue....

Limula team

3 February 2023

Making personalized cancer therapies accessible to all

CSEM has supported Lausanne-based start-up Limula in its mission to make cell therapies more affordable, and to facilitate access to these personalized treatments. ...